Signet Therapeutics Co. Ltd. has divulged α, β-unsaturated amide compounds acting as transcriptional enhancer factor (TEAD) inhibitors reported to be useful for the treatment of cancer.
Scientists at Livzon Pharmaceutical Group Inc., Shanghai Institute of Organic Chemistry and the University of Michigan have identified proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase binding moiety covalently bound to a cyclin-dependent kinase 12 (CDK12) and 13 (CDK13) targeting moiety through a linker reported to be useful for the treatment of cancer.
The State University of New Jersey (Rutgers) has synthesized non-structural protein 3 (nsp3; PL-pro) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of viral infections.
Jiangsu Chia Tai Fenghai Pharmaceutical Co. Ltd. has described cyclin-dependent kinase 7 (CDK7) inhibitors reported to be useful for the treatment of cancer.
2A Biosciences Inc. has divulged compounds acting as 5-HT2A and 5-HT2C receptor agonists reported to be useful for the treatment of atopic dermatitis, conjunctivitis, Crohn’s disease, type 2 diabetes, obsessive-compulsive disorder, rheumatoid arthritis, schizophrenia and traumatic brain injury, among others.
Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has identified protein arginine N-methyltransferase 5 (PRMT5)/methylosome protein 50 (MEP50) interaction inhibitors reported to be useful for the treatment of cancer.
Shenzhen Genuine Biotech Co. Ltd. has disclosed stimulator of interferon genes protein (STING; TMEM173) agonists reported to be useful for the treatment of cancer. An exemplified compound significantly reduced tumor growth in experiments.
RSS